Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study

Ko, Ryo; Shukuya, Takehito; Okuma, Yusuke; Tateishi, Kazunari; Imai, Hisao; Iwasawa, Shunichiro; Miyauchi, Eisaku; Fujiwara, Akiko; Sugiyama, Tomohide; Azuma, Keisuke; Muraki, Keiko; Yamasaki, Masahiro; Tanaka, Hisashi; Takashima, Yuta; Soda, Sayo; Ishimoto, Osamu; Koyama, Nobuyuki; Morita, Satoshi; Kobayashi, Kunihiko; Nukiwa, Toshihiro; Takahashi, Kazuhisa

doi:10.1634/theoncologist.2017-0586

Cited by 24 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADOC chemotherapy is a useful regimen for advanced and metastatic thymic carcinoma ( 4 , 6 ) but not esophageal carcinoma. Four cycles of ADOC chemotherapy were effective for both the anterior mediastinal and intraesophageal masses in our case.…”

Section: Discussionmentioning

confidence: 99%

“…Thymic carcinoma is a thymic epithelial neoplasm with cytological malignant features and a clinical course that tends to be much more aggressive than that of thymoma (1,2). Thymic carcinoma, located in the anterosuperior mediastinum, frequently spreads to the pleural space, regional lymph nodes, liver, and lung (1)(2)(3)(4)(5)(6). The initial clinical presentations in patients with thymic carcinoma include chest pain, cough, and superior vena cava syndrome (5,6).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Direct Intraesophageal Growth from Metastatic Mediastinal Lymphadenopathy in Thymic Carcinoma

et al. 2021

View full text Add to dashboard Cite

We herein report a case of thymic carcinoma that initially exhibited dysphagia and an intraesophageal mass lesion. A 68-year-old man was admitted to our hospital because of dysphagia. An endoscopic examination revealed a mass on the middle esophagus. Chest computed tomography (CT) showed a huge anterior mediastinal mass and subcarinal lymph node swelling, directly invading into the esophageal lumen. An immunohistological examination of the esophageal and anterior mediastinal masses revealed squamous cell carcinoma originating from the thymus. This is the first report of a thymic carcinoma spreading into the esophageal lumen and forming a mass lesion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Direct Intraesophageal Growth from Metastatic Mediastinal Lymphadenopathy in Thymic Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A Cox proportional hazards model was used to identify the prognostic factors for PFS and OS, with statistically signi cant variables used for the univariate model and clinically important variables further analyzed using multivariate analysis. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria), and statistical signi cance was set at P < 0.05 [15] .…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factor in Patients with Advanced, Inoperable Thymic Carcinoma: An Application of the Lung Immune Prognostic Index

Araki

Tateishi

Komatsu

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The prognostic implications of palliative chemotherapy for advanced or recurrent thymic carcinomas require full elucidation. The lung immune prognostic index (LIPI) is a novel prognostic index whose effectiveness has recently been reported in lung cancer patients. This study aimed to evaluate the LIPI’s clinical value in advanced or recurrent thymic carcinoma patients. Methods: We retrospectively analyzed 41 advanced or recurrent thymic carcinoma patients undergoing palliative chemotherapy between January 2001 and December 2020. Survival-time analysis was conducted using the Kaplan–Meier method and log-rank test. Multivariate analysis using the Cox proportional hazards model was performed to investigate the LIPI’s predictive and/or prognostic value.Results: Median progression-free survival (PFS) for first line chemotherapy and overall survival (OS) were significantly longer in the good-LIPI group (LIPI: 0) than in the intermediate/poor-LIPI group (LIPI: 1 or 2) (PFS: 13.4 vs. 6.8 months, p=0.0425; OS: 48.2 vs. 28.9 months, p=0.00506.). Multivariate analysis revealed that serum albumin <3.5 g/dL and an intermediate/poor LIPI were independent adverse prognostic factors for OS. Moreover, an intermediate/poor LIPI was the only adverse prognostic factor for PFS. Conclusions: Our study indicates that the LIPI is a potential prognostic marker in patients with advanced or recurrent thymic carcinoma undergoing palliative chemotherapy.

show abstract

“…Details of the study design and results regarding the efficacy of first-line chemotherapy in patients with advanced thymic carcinoma have been published previously [22]. In this observational multicenter study, we retrospectively reviewed the medical records of patients diagnosed and treated in Japan between April 1995 and March 2014.…”

Section: Study Cohortmentioning

confidence: 99%

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study

Tateishi

Shukuya

et al. 2019

The Oncologist

Self Cite

View full text Add to dashboard Cite

Background. Owing to the rarity of this tumor, there is limited information about second-line chemotherapy for patients with previously treated advanced thymic carcinoma. Material and Methods. We performed a multi-institutional, retrospective study named NEJ023 for patients with advanced thymic carcinoma. Patients without indications for curative treatment were treated with chemotherapy from 1995 to 2014 at 40 institutions in the North East Japan Study Group. Demographic and clinicopathologic characteristics, data on treatment methods, and outcomes of second-line chemotherapy were obtained from medical records. Results. In total, 191 patients were enrolled in this study. Second-line chemotherapy included platinum-based doublets in 57.6% of patients, other multidrug chemotherapy (e.g., cisplatin, doxorubicin, vincristine, and cyclophosphamide) in 13.6%, and monotherapy in 28.8%. The median follow-up

show abstract

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study

Cited by 24 publications

References 26 publications

Direct Intraesophageal Growth from Metastatic Mediastinal Lymphadenopathy in Thymic Carcinoma

Direct Intraesophageal Growth from Metastatic Mediastinal Lymphadenopathy in Thymic Carcinoma

Prognostic Factor in Patients with Advanced, Inoperable Thymic Carcinoma: An Application of the Lung Immune Prognostic Index

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study

Contact Info

Product

Resources

About